Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

被引：22

作者：

Li, Heidi Oi-Yee ^{[1
]}

Colantonio, Sophia ^{[1
]}

Ramien, Michele L. ^{[2
,3
]}

机构：

[1] Univ Ottawa, Fac Med, Ottawa, ON, Canada

[2] Childrens Hosp Eastern Ontario, Div Rheumatol & Dermatol, Ottawa, ON, Canada

[3] Alberta Childrens Prov Gen Hosp, Div Community Pediat, Calgary, AB, Canada

来源：

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2019年 / 23卷 / 06期

关键词：

case series; cyclosporine; cyclosporine A; Fuchs syndrome; MIRM; Mycoplasma pneumoniae-induced rash and mucositis; mucositis; mycoplasma; Mycoplasma pneumoniae-associated mucositis; MPAM; pediatric; Stevens-Johnson syndrome; S[!text type='JS']JS[!/text; therapeutics; STEVENS-JOHNSON-SYNDROME; DOXYCYCLINE;

D O I：

10.1177/1203475419874444

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin . Objective: This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM. Methods: The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients. Results: Rapid clinical resolution was observed following CsA therapy. Conclusions: We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.

引用

页码：608 / 612

页数：5

共 16 条

[1]

Amor KT, 2010, J AM ACAD DERMATOL, V63, P925, DOI 10.1016/j.jaad.2010.02.063

[2]

Bhutani T, 2013, COMPREHENSIVE DERMAT, V3th, P199

[3] Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: A systematic review [J].